Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 120

Sort by

Sort Order Select

Journal Articles

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Blood (2024) 144 (Supplement 1): 3563.

https://doi.org/10.1182/blood-2024-200574

Published: 2024

Journal Articles

Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party

Blood (2024) 144 (Supplement 1): 3540.

https://doi.org/10.1182/blood-2024-198741

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

Eva Rettinger, Martin Hutter, Birte Karschen, Evangelia Antoniou, Peter Bader, Rita Beier, Birgit Burkhardt, Ursula Creutzig, Gabriele Escherich, Jan-Henning Klusmann, Peter Lang, Naghmeh Niktoreh, Martin G. Sauer, Stephanie Sendker, Dirk Reinhardt, Katharina Waack

Blood (2024) 144 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2024-208311

Published: 2024

Journal Articles

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Blood (2024) 144 (Supplement 1): 7225.

https://doi.org/10.1182/blood-2024-201825

Published: 2024

Journal Articles

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Blood (2024) 144 (Supplement 1): 5079.

https://doi.org/10.1182/blood-2024-203643

Published: 2024

Journal Articles

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Blood (2024) 144 (Supplement 1): 4864.

https://doi.org/10.1182/blood-2024-203358

Published: 2024

Journal Articles

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Blood (2023) 142 (Supplement 1): 4927.

https://doi.org/10.1182/blood-2023-174492

Published: 2023

Journal Articles

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Blood (2023) 142 (Supplement 1): 2189.

https://doi.org/10.1182/blood-2023-177715

Published: 2023

Journal Articles

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Dr. Peters, Peter Bader, Ulrike Pötschger, M. Akif Yesilipek, Herbert Pichler, Franco Locatelli, Raquel Staciuk, Adriana Balduzzi, Gergely Krivan, Marianne Ifversen, Cristina Díaz De Heredia, Marc Bierings, Jacek Wachowiak, Jean-Hugues Dalle

Blood (2023) 142 (Supplement 1): 3548.

https://doi.org/10.1182/blood-2023-185870

Published: 2023

Journal Articles

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

Maike Breidenbach, Peter Bader, Andishe Attarbaschi, Claudia Rossig, Roland Meisel, Markus Metzler, Marion Subklewe, Fabian Mueller, Paul-Gerhardt Schlegel, Irene Teichert von Lüttichau, Jean-Pierre Bourquin, Gabriele Escherich, Gunnar Cario, Peter Lang, Ramona Krauss, Arend von Stackelberg, Semjon Willier, Christina Peters, Tobias Feuchtinger

Blood (2023) 142 (Supplement 1): 2135.

https://doi.org/10.1182/blood-2023-190117

Published: 2023

Journal Articles

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Blood (2023) 142 (Supplement 1): 779.

https://doi.org/10.1182/blood-2023-172955

Published: 2023

Journal Articles

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Anita Lawitschka, Jean-Hugues Dalle, Ulrike Pötschger, Helga Arnardottir, Petr Sedlacek, Jochen Büchner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Díaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Franco Locatelli, Christina Peters, Peter Bader

Blood (2023) 142 (Supplement 1): 110.

https://doi.org/10.1182/blood-2023-186850

Published: 2023

Journal Articles

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Krzysztof Kalwak, Peter Bader, Jean-Hugues Dalle, Petr Sedlacek, Jochen Buechner, Marianne Ifversen, Peter Svec, Jerry Stein, Tayfun Güngör, Jacek Toporski, Cristina Diaz De Heredia, Marc Bierings, Roland Meisel, Marc Ansari, Adriana Balduzzi, Ulrike Poetschger, Dr. Peters, Franco Locatelli

Blood (2023) 142 (Supplement 1): 232.

https://doi.org/10.1182/blood-2023-180728

Published: 2023

Journal Articles

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Blood (2023) 142 (Supplement 1): 1050.

https://doi.org/10.1182/blood-2023-187587

Published: 2023

Journal Articles

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Rakesh Awasthi, Edward Waldron, Stephan Grupp, Michael A. Pulsipher, Peter Bader, Stephen J Schuster, Richard T Maziarz, Edmund K. Waller, Ulrich Jaeger, Catherine Thieblemont, Martin Dreyling, Nathan Fowler, Harald Jakob Maier, Jennifer Willert

Blood (2023) 142 (Supplement 1): 4872.

https://doi.org/10.1182/blood-2023-181663

Published: 2023

Journal Articles

Allo or auto CAR-T cells for refractory BCP-ALL?

Peter Bader

Blood (2023) 142 (2): 122–124.

https://doi.org/10.1182/blood.2023020814

Published: 2023

Journal Articles

Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial

Christina Peters, Ulrike Poetschger, Jean-Hugues Dalle, Akif Yesilipek, Jerry Stein, Herbert Pichler, Adriana Balduzzi, Franco Locatelli, Petr Sedlacek, Jacek Wachowiak, Tayfun Güngör, Marianne Ifversen, Marleen Renard, Tony H Truong, Raquel Staciuk, Peter J. Shaw, Gergely Kriván, Jochen Büchner, Peter Bader

Blood (2022) 140 (Supplement 1): 897–899.

https://doi.org/10.1182/blood-2022-168609

Published: 2022

Journal Articles

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Blood (2022) 140 (Supplement 1): 12938–12940.

https://doi.org/10.1182/blood-2022-162484

Published: 2022

Journal Articles

Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial

Franco Locatelli, Peter Bader, Jean-Hugues Dalle, Ulrike Poetschger, Herbert Pichler, Petr Sedlacek, Jochen Büchner, Peter J. Shaw, Marianne Ifversen, Raquel Staciuk, Kim Vettenranta, Adriana Balduzzi, Christina Peters

Blood (2022) 140 (Supplement 1): 4865–4867.

https://doi.org/10.1182/blood-2022-166048

Published: 2022

Journal Articles

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Blood (2022) 140 (Supplement 1): 10895–10896.

https://doi.org/10.1182/blood-2022-166636

Published: 2022

NARROW

Addition of Anti-T-Lymphocyte-Globuline As Graft Versus Host Disease Prophylaxis for Matched Unrelated Donors Equalizes Outcomes with Matched Sibling Donors: Results from the AML SCT-BFM 2007 Trial

Total Body Irradiation Versus Chemotherapy Conditioning before Allogeneic Hematopoietic Stem Cell Transplantation for Pediatric Acute Lymphoblastic Leukemia Patients Aged 2 to 4 Years: A Retrospective Study of the EBMT Pediatric Diseases Working Party

Allogeneic Hematopoietic Stem Cell Transplantation in Pediatric Acute Myeloid Leukemia: Results of the AML BFM Study Group

WUC007-03: A Phase 2 Study of Anti-CD7 Allogenic CAR-T Cells (WT-7) in Patients with Relapsed/Refractory (R/R) T-Cell Acute Lymphoblastic Leukemia (T-ALL)/Lymphoblastic Lymphoma (LBL)

Allogeneic Hematopoietic Stem Cell Transplantation (allo-HSCT) Outcomes in Leukocyte Adhesion Deficiency Type -I

Comparative Results of Pediatric Patients with ALL Receiving Either of Two Different Types of Human Anti-T Lymphocyte Globulin Prior to Hematopoietic Stem Cell Transplantation: Findings from the International Prospective Forum Study

Real-World Data Suggest Effectiveness of Allogeneic Mesenchymal Stromal (MSC-FFM) Cells in Ruxolitinib-Refractory Acute Graft-Versus-Host Disease

Graft-Versus-Host Disease after Anti-CD19 Chimeric Antigen Receptor T-Cell Infusion Post Allogeneic Hematopoietic Cell Transplantation: A Transplant Complications and Paediatric Disease Working Parties EBMT Joint Study

Similar Overall Survival and Event-Free Survival for Patients Under or over the Age of 14 Years, but More Chronic Graft Versus Host Disease and Non-Relapse Mortality in the “Older” Patients

Multinational Retrospective Analysis of Bridging Therapy Prior to Chimeric Antigen Receptor T Cells for Relapsed/Refractory Acute Lymphoblastic Leukemia in Children and Young Adults

A Day 14 Endpoint for Acute Gvhd Clinical Trials

Moderate Incidence but Striking Correlation with TBI of Secondary Malignancies after HSCT in Children with ALL: Long-Term Follow-up from the Prospective International BFM- and Forum-Trials

Comparable Outcome after Busulfan- or Treosulfan-Based Conditioning Regimen in Children Above 4 Years of Age with ALL Undergoing Allogeneic HSCT. Results from the Prospective International Forum-Trial

Outcome of Children with B-Cell Precursor Acute Lymphoblastic Leukemia (BCP-ALL) with Hypodiploidy or BCR-ABL1 Fusion Given Allogeneic Hematopoietic Stem Cell Transplantation (HSCT): Results from the Prospective Forum Study

Long Term Durable Responses in Relapsed/Refractory (r/r) ALL, DLBCL, and FL Patients Treated with Tisagenlecleucel and Its Association with Persistence of CAR T-Cells

Allo or auto CAR-T cells for refractory BCP-ALL?

Relapse Is the Most Common Treatment Failure Post HSCT in Children with ALL below 4 Years of Age Given a Chemo-Based Conditioning Regimen. Results from the Prospective Multinational Forum-Trial

The Impact of Pre-Transplant Extramedullary Disease on the Outcome of Allogeneic Hematopoietic Cell Transplantation for Acute Myeloid Leukemia in Children- on Behalf of PDWP/EBMT

Long-Term Data Confirm the Superiority of Total Body Irradiation-Containing Conditioning Regimen in Comparison to a Chemotherapy-Based Preparation in Children with Acute Lymphoblastic Leukemia Above the Age of 4 Years Given an Unmanipulated Allograft. Results of the Forum Randomized Clinical Trial

Outcomes of Allogeneic Hematopoietic Stem Cell Transplantation for Congenital Amegakaryocytic Thrombocytopenia, a PDWP/EBMT Study

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only